Puma Biotechnology
PBYI
144 hedge funds and large institutions have $394M invested in Puma Biotechnology in 2019 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 55 increasing their positions, 28 reducing their positions, and 30 closing their positions.
96% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 28
17% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 30
3.95% more ownership
Funds ownership: 90.05% → 94% (+3.9%)
4% more funds holding
Funds holding: 139 → 144 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less capital invested
Capital invested by funds: $442M → $394M (-$48.4M)
18% less call options, than puts
Call options by funds: $6.45M | Put options by funds: $7.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$9.19M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$5.99M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$5.82M |
| 4 |
MAM
Melqart Asset Management
London,
United Kingdom
|
+$5.71M |
| 5 |
FAM
Fred Alger Management
New York
|
+$5.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.22M |
| 3 |
SIM
Spark Investment Management
New York
|
-$3.34M |
| 4 |
Renaissance Technologies
New York
|
-$3.21M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.13M |
PBYI Hedge Fund Activity: Q3 2019 in Review
144 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2019, worth a combined $394M — down 11% from $442M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new PBYI positions and 30 closed out — a net gain of 5 holders — while 55 added to existing stakes and 28 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $9.19M. The largest seller was State Street, cutting an estimated $19.4M.
- 144 institutional investors held Puma Biotechnology (PBYI) as of Q3 2019, up from 139 in Q2 2019.
- Funds reported $394M of Puma Biotechnology stock for Q3 2019, down 11% quarter-over-quarter.
- 35 funds opened new Puma Biotechnology positions in Q3 2019 and 30 closed out, a net change of +5 holders.
- The largest Puma Biotechnology buyer in Q3 2019 was PFM Health Sciences, an estimated $9.19M added.
- The largest Puma Biotechnology seller in Q3 2019 was State Street, an estimated $19.4M sold.
Based on aggregated 13F filings for Q3 2019.